Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Completed · Phase 3

Conditions studied: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

In brief

The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Key facts

Study ID
NCT03391466
Run by
Kite, A Gilead Company
People needed
359
Starts
2018-01-25
Expected to finish
2024-11-25
Last updated by the study team
2025-12-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.